Tasso develops clinical‑quality, virtually painless blood collection devices paired with an integrated logistics platform to enable decentralized health testing for pharma, research, and healthcare customers. Its products allow users to collect blood at convenient times and locations, increasing access to remote populations and reducing clinic visit burdens. The company’s devices are used in decentralized clinical trials, clinical research, and remote patient monitoring globally. Tasso plans to use new capital to scale manufacturing and operations to meet rising demand for at‑home testing driven by the COVID‑19 pandemic. The company emphasizes partnerships with pharmaceutical companies, academic institutions, and payers to deliver actionable health data. Tasso is headquartered in Seattle, Washington and is privately held. Tasso develops clinical-grade, at-home self-sampling blood-collection devices called Tasso OnDemand that enable virtually painless blood collection with a push-button workflow. Collected samples are mailed to CLIA-certified, high-complexity laboratories for analysis. The products are being validated for routine diagnostics, chronic disease monitoring, infectious disease surveillance, athletic and sports testing, virtual clinical trials, global health, and care for underserved populations, and are being adopted by academic medical institutions, government agencies, comprehensive cancer centers, and pharmaceutical organizations. Tasso plans to scale manufacturing and operations to meet growing demand and to enhance the platform with new value-added services. The company is headquartered in Seattle and is privately held, funded by grants, private investments, and co-development collaborations. Tasso recently completed an oversubscribed $17 million Series A and has raised $38.6 million in total to date. Tasso develops Tasso OnDemand, a self-collection blood-sampling product that lets people collect blood at home and mail samples to labs for analysis. The company positions the product to improve drug development and clinical care by enabling frequent measurement of blood markers. Tasso expects Tasso OnDemand to be available for purchase in Q2 2019 and plans to scale the product and grow the team to meet commercial demand. The business has attracted commercial interest from pharmaceutical and lab partners and pursues co-development deals with industry leaders. Tasso is privately held and headquartered in Seattle, Washington. Its technology development was supported by $13.1 million in grant funding from DARPA, DTRA, and the NIH.

Total raised

$123M

Funding rounds

3

Latest round

Series B

Latest activity

Dec 2021